Jonathan Rosenberg, ESMO 2022: Study EV-103 Cohort K – Enfortumab vedotin in combination with pembrolizumab in locally advanced or metastatic urothelial cancer
As there is a current need for effective and tolerable first line treatment options in patients with locally advanced or metastatic urothelial cancer (la/mUC), Dr Jonathan Rosenberg (Memorial Sloan Kettering Cancer Center, New York, NY, USA) joins touchONCOLOGY to discuss the positive results from Study EV-103 Cohort K. The study data supports ongoing investigations of first line enfortumab vedotin monotherapy or in combination with pembrolizumab in patients with la/mUC who have a high unmet need. Dr Rosenberg also highlights further clinical trial that are ongoing for the treatment of la/mUC.
The abstract entitled ‘Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)‘ Abstract LBA73, was presented at European Society for Medical Oncology (ESMO) 2022.
- What are the major unmet needs in the first-line treatment of locally advanced or metastatic urothelial cancer? (0:13)
- What is the rationale for investigating the combination of enfortumab vedotin and pembrolizumab in this treatment setting? (1:08)
- What were the design and eligibility criteria of Study EV-103? (2:08)
- What were the efficacy and safety findings of the study? (3:03)
- What further investigations of this combined therapy are planned? (4:05)
Disclosures: Jonathan Rosenberg is a consultant for Astellas, Seagen, Gilead, and Merck; receives grant/research support from Astellas, and Seagen; is on the advisory board for Astellas, Seagen, Gilead, and Merck; and receives honoraria/honorarium from Pfizer, and EMD-Serono.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
Filmed in coverage of ESMO 2022
Share this Video
Related Videos In Genitourinary Cancer
Looking to the future with Arnulf Stenzl: What can we hope to see in urological oncology in the next 5 years?
Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, discusses what he hopes to see in the field of uro-oncological surgery in the next five years. He hopes this will include improving early detection of prostate cancer and therefore the possibility of avoiding surgery; improving prognostic factors and diagnosis in early disease […]
Arnulf Stenzl, EAU23: Latest developments in urological oncology
It was a pleasure to hear from the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the pivotal new projects and initiatives the society are currently working on. Topics covered Minimalise any uro-oncologic surgery, more precise, complete removal of tumour, improving outcomes (00:37) Developments in robot-assisted surgery […]
Arnulf Stenzl: Pivotal new projects of the European Association of Urology (EAU)
It was a pleasure to hear from the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the pivotal new projects and initiatives the society are currently working on. Topics covered Meetings and introducing more virtual, web-based education post-COVID (00:20) Projects, real-world data, future strategies (3:30) Development of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!